


The claims defining the invention are as follows:

1. A compound of Formula (I),



Formula I

or a pharmaceutically acceptable salt thereof,

wherein:

R¹ is C₁₋₆ alkyl optionally substituted with 1 to 3 R^{1A}, C₃₋₈ cycloalkyl optionally substituted with 1 to 4 R^{1B}, or 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1C};

each R^{1A} is independently halogen, -OH, -CN, C₁₋₂ haloalkyl, -C(O)NR^XR^Y, C₆₋₁₀ aryl optionally substituted with 1 to 3 R^{1D}, or a 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1D}, provided no more than 1 R^{1A} is C₆₋₁₀ aryl optionally substituted with 1 to 3 R^{1D} or 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S;

each R^{1B} is independently -CN, halogen, C₁₋₆ alkyl optionally substituted with 1 to 3 -OH or -NR^aR^b, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₂ haloalkyl, C₃₋₆ cycloalkyl, -C(O)NR^XR^Y, or a 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D}, provided no more than 1 R^{1B} is C₃₋₆ cycloalkyl or 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S;

each R^{1C} is independently C₁₋₆ alkyl, oxo, C₁₋₄ haloalkyl, -C(O)H, -C(O)C₁₋₄ alkyl, -C(O)OC₁₋₄ alkyl, or a 5 to 12 membered heteroaryl having 1 to 3

heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} , provided no more than 1 R^{1C} is a 5 to 12 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S;

each R^X is independently $-H$, C_{3-6} cycloalkyl, C_{1-6} alkyl optionally substituted with 1 to 3 R^Z , 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z ;

each R^Y is independently $-H$ or C_{1-6} alkyl optionally substituted with 1 to 3 R^Z ;


or R^X and R^Y are taken together to form a 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z ;

wherein each R^Z is independently halogen, methyl, ethyl, oxo, $-OH$, $-S(O)_2C_{1-3}alkyl$, or 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S;

each R^a is $-H$, $C_{1-3}alkyl$, or a 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z ;

each R^b is $-H$ or $C_{1-3}alkyl$; or

R^a and R^b taken together form a 3 to 8 membered monocyclic or bicyclic heterocycle optionally substituted with 1 to 3 R^Z ;



the moiety is a pyrrolidine or a 5-7 membered bicyclic heterocycle having one nitrogen, optionally substituted with 1 to 6 R^2 groups;

wherein each R^2 is independently halogen, $C_{1-3}alkyl$, $-OH$, or $-OC_{1-3}alkyl$;

R^3 is $-H$, halogen, or $C_{1-4}alkyl$;

R^4 is phenyl optionally substituted with 1 to 5 R^{4A} , or pyridinyl optionally substituted with 1 to 4 R^{4B} ; and

each R^{1D} , R^{4A} , and R^{4B} are independently $-\text{CN}$, halogen, C_{1-4} alkyl, $-\text{OC}_{1-4}\text{alkyl}$, $-\text{OC}_{1-4}\text{haloalkyl}$, or $\text{C}_{1-4}\text{haloalkyl}$.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is phenyl optionally substituted with 1 to 3 R^{4A} .


3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each R^{4A} is independently Cl , F , $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CH}_3$, $-\text{OCF}_3$, $-\text{OCF}_2\text{H}$, or $-\text{CN}$.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-\text{Cl}$ or $-\text{CH}_3$.



5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-\text{CH}_3$.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt






7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt



8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II)



Formula II

wherein:

R^1 is C_{1-6} alkyl optionally substituted with 1 to 3 R^{1A} , C_{3-8} cycloalkyl optionally substituted with 1 to 4 R^{1B} , or 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1C} ;

each R^{1A} is independently halogen, $-OH$, $-CN$, C_{1-2} haloalkyl, $-C(O)NR^X R^Y$, C_{6-10} aryl optionally substituted with 1 to 3 R^{1D} , or a 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1D} , provided no more than 1 R^{1A} is C_{6-10} aryl optionally substituted with 1 to 3 R^{1D} or 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S;

each R^{1B} is independently halogen, C_{1-6} alkyl optionally substituted with 1 to 3 $-OH$ or $-NR^a R^b$, C_{1-4} alkoxy, C_{1-2} haloalkyl, $-C(O)NR^X R^Y$, or 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} , provided no more than 1 R^{1B} is 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S;

each R^{1C} is independently C_{1-6} alkyl, oxo, C_{1-4} haloalkyl, $-C(O)H$, $-C(O)C_{1-4}$ alkyl or $-C(O)OC_{1-4}$ alkyl;

each R^X is independently $-H$, C_{3-6} cycloalkyl, C_{1-6} alkyl optionally substituted with 1 to 3 R^Z , 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z ;

each R^Y is independently $-H$ or C_{1-6} alkyl optionally substituted with 1 to 3 R^Z ;

or R^X and R^Y are taken together to form a 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z

wherein each R^Z is independently halogen, methyl, ethyl, oxo, $-OH$, $-S(O)_2C_{1-3}alkyl$, or 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S;

each R^a is $-H$, $C_{1-3}alkyl$, or a 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^Z ;

each R^b is $-H$ or $C_{1-3}alkyl$; or

R^a and R^b taken together form a 3 to 8 membered monocyclic or bicyclic heterocyclyl optionally substituted with 1 to 3 R^Z ;


each of R^{2A} , R^{2B} , R^{2C} , R^{2D} , R^{2E} , and R^{2F} are independently $-H$, halogen, $C_{1-3}alkyl$, $-OH$, or $-OC_{1-3}alkyl$, or R^{2C} or R^{2D} may be taken together with R^{2E} or R^{2F} to form a cyclopropyl group;

R^3 is halogen or methyl;

R^4 is phenyl optionally substituted with 1 to 5 R^{4A} , or pyridinyl, optionally substituted with 1 to 4 R^{4B} ; and


each R^{1D} , R^{4A} , and R^{4B} are independently $-CN$, halogen, $C_{1-4}alkyl$, $-OC_{1-4}alkyl$, $-OC_{1-4}haloalkyl$, or $C_{1-4}haloalkyl$.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III)




Formula III

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IIIa)




Formula IIIa

11. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IV):



Formula IV

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^1 is C_{1-6} alkyl optionally substituted with 1 to 3 R^{1A} .
13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl, ethyl, propyl, butyl, or pentyl, optionally substituted with 1 to 3 R^{1A} .
14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R^1 is ethyl or butyl optionally substituted with C_{1-2} haloalkyl.
15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^1 is



16. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R^1 is ethyl, propyl, or butyl optionally substituted with 1 to 3 R^{1A} , wherein each R^{1A} is independently C_{1-2} haloalkyl, $-OH$, $-C(O)NH_2$, $-C(O)NH(C_{1-3}alkyl)$, or $-C(O)N(C_{1-3}alkyl)_2$.

[illegible]

19. The compound of any one of claims 1 to 11 or 18, or a pharmaceutically acceptable salt thereof, wherein R¹ is cyclopropyl or cyclobutyl, optionally substituted with 1 to 3 R^{1B}.

21. The compound of any one of claims 1 to 11 or 18 to 20, or a pharmaceutically acceptable salt thereof, wherein each R^{1B} is independently fluoro, -CH₂NR^aR^b or -C(O)NR^xR^y.

R^b is -H; or

R^a and R^b are taken together to form a 4 to 7 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^Z ;

R^X is methyl or a 4 to 7 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^Z ;

R^Y is $-H$;


or R^X and R^Y are taken together to form a 4 to 7 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^Z .

23. The compound of any one of claims 1 to 11 or 18 to 22, or a pharmaceutically acceptable salt thereof, wherein 1 or 2 R^{1B} is optionally fluoro and one R^{1B} is $-CH_2NR^aR^b$, where R^a is thietanyl substituted with 1 to 3 oxo or methyl groups or 2-oxa-6-azaspiro[3.3]heptanyl and R^b is $-H$ or R^a and R^b are taken together to form 2-oxa-6-azaspiro[3.3]heptanyl.

24. The compound of any one of claims 1 to 11 or 18 to 23, or a pharmaceutically acceptable salt thereof, wherein 1 or 2 R^{1B} is optionally fluoro and one R^{1B} is $-C(O)NR^XR^Y$, wherein R^X is methyl or thietanyl optionally substituted with 1 to 3 methyl or oxo groups, R^Y is $-H$, or R^X and R^Y are taken together to form 2-oxa-6-azaspiro[3.3]heptanyl, 2-thia-6-azaspiro[3.3]heptan-6-yl, azetidiny, 2,6-diazaspiro[3.3]heptanyl, 6-oxa-1-azaspiro[3.3]heptan-1-yl, each of which is optionally substituted with 1 to 3 groups that are independently fluoro, oxo, methyl, or $-S(O)_2CH_3$.

25. The compound of any one of claims 1 to 11 or 18 to 21, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 halogens and $-C(O)NR^XR^Y$, wherein R^X is $-H$ or C_{1-6} alkyl optionally substituted with 1 to 3 R^Z and R^Y is $-H$ or C_{1-6} alkyl optionally substituted with 1 to 3 R^Z .

26. The compound of any one of claims 1 to 11, 18 to 21, or 25, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclobutyl substituted with 2 halogens and - $C(O)NR^X R^Y$, wherein R^X is C_{1-3} alkyl and R^Y is $-H$.
27. The compound of any one of claims 1 to 11 or 18 to 20, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 halogens and a 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} .
28. The compound of any one of claims 1 to 11, 18 to 20, or 27, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 halogen and a 5 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} .
29. The compound of any one of claims 1 to 11, 18 to 20, 27, or 28, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 fluoro and triazolyl or thiadiazolyl.
30. The compound of any one of claims 1 to 11, 18 to 20, or 27 to 29, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 fluoro and triazolyl.
31. The compound of any one of claims 1 to 9 or 18 to 30, or a pharmaceutically acceptable salt thereof, wherein R^1 is



32. The compound of any one of claims 1 to 11 or 18, or a pharmaceutically acceptable salt thereof, wherein R^1 is C_{3-5} cycloalkyl optionally substituted with 1 to 4 R^{1B} , wherein:


each R^{1B} is independently halogen, ethynyl, $-CN$, C_{1-3} alkyl substituted with $-OH$, or $-NR^aR^b$, $-C(O)NR^XR^Y$, or 5 to 8 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} .

33. The compound of any one of claims 1 to 11, 18, or 32, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl, bicyclo[1.1.1]pentanyl, cyclobutyl optionally substituted with 1 to 3 R^{1B} wherein:

each R^{1B} is independently halogen, ethynyl, $-CN$, C_{1-3} alkyl substituted with $-OH$ or $-NR^aR^b$, $-C(O)NR^XR^Y$, or 5 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S optionally substituted with 1 to 3 R^{1D} .

34. The compound of any one of claims 1 to 11, 18 to 20, 27, 28, 32, or 33, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyclopropyl or cyclobutyl, optionally substituted with 1 or 2 fluoro and one of oxadiazolyl optionally substituted with C_{1-3} alkyl, triazolyl optionally substituted with C_{1-3} alkyl, or thiadiazolyl.

35. The compound of any one of claims 1 to 11, 18 or 19, or a pharmaceutically acceptable salt thereof, wherein R^1 is




36. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^1 is a 3 to 8 membered monocyclic or bicyclic heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1C} .

37. The compound of any one of claims 1 to 11 or 36, or a pharmaceutically acceptable salt thereof, wherein R^1 is a 3 to 5 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R^{1C} .


38. The compound of any one of claims 1 to 11, 36, or 37, or a pharmaceutically acceptable salt thereof, wherein R^1 is oxetanyl or thietanyl optionally substituted with 1 to 3 R^{1C} .

39. The compound of any one of claims 1 to 11 or 36 to 38, or a pharmaceutically acceptable salt thereof, wherein each R^{1C} is independently C_{1-3} alkyl, $-CF_3$, or oxo.

40. The compound of any one of claims 1 to 11 or 36 to 39, or a pharmaceutically acceptable salt thereof, wherein R^1 is



41. The compound of any one of claims 1 to 11 or 36 to 38, or a pharmaceutically acceptable salt thereof, wherein R^1 is.




42. The compound of any one of claims 8 or 12 to 41, wherein R^{2C} is taken together with R^{2E} to form a cyclopropyl group and R^{2D} and R^{2F} are each $-H$.


43. The compound of any one of claims 8 or 12 to 42, or a pharmaceutically acceptable salt thereof, wherein R^{2A} and R^{2B} are $-H$.


44. The compound of any one of claims 1, or 4 to 43 or a pharmaceutically acceptable salt thereof, wherein R^4 is pyridinyl, optionally substituted with 1 to 4 R^{4B} .


45. The compound of claim 44, wherein R^4 is pyridin-4-yl, optionally substituted with 1 to 3 groups selected from F , Cl , CF_3 , and CHF_2 .


46. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, which is
















47. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, which is




















48. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, which is






49. The compound of any one of claims 1 to 45 or 48, which is




pharmaceutically acceptable salt thereof.

50. The compound of any one of claims 1 to 45 or 49, which is




or a pharmaceutically acceptable salt thereof.

51. The compound of any one of claims 1 to 45 or 49, which is




or a pharmaceutically acceptable salt thereof.

52. The compound of any one of claims 1 to 45 or 49, which is




or a pharmaceutically acceptable salt thereof.

53. The compound of any one of claims 1 to 45 or 49, which is




or a pharmaceutically acceptable salt thereof.

54. The compound of any one of claims 1 to 45 or 49, which is



or a pharmaceutically acceptable salt thereof.

55. The compound of any one of claims 1 to 45 or 49, which is



or a pharmaceutically acceptable salt thereof.

56. A pharmaceutical composition comprising a compound of any one of claims 1 to 55 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

57. The pharmaceutical composition of claim 56, further comprising one or more additional therapeutic agents.

58. The pharmaceutical composition of claim 57, wherein the one or more additional therapeutic agents are selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis b surface antigen (HBsAg) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin inhibitors, HBV viral entry inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA) and ddRNAi endonuclease modulators, ribonucleotide reductase inhibitors, HBV E antigen inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor agonists, HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant

thymosin alpha-1, bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors, and other HBV drugs.

59. The pharmaceutical composition of claim 57 or 58, wherein the one or more additional therapeutic agents are selected from adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), and lamivudine (EPIVIR-HBV[®]).

60. The pharmaceutical composition of claim 57 or 58, wherein one or more additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

61. A compound of any of claims 1 to 55, or a pharmaceutically acceptable salt thereof for use in medical therapy.

62. Use of compound of any of claims 1 to 55, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a HBV infection in a human.

63. The use according to claim 62, wherein the compound is combined with one or more additional therapeutic agents.

64. The use according to claim 62, wherein the medicament is for co-administration with one or more additional therapeutic agents.

65. The use according to claim 63 or 64, wherein the one or more additional therapeutic agents are selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators toll-like receptor (TLR) modulators, interferon alpha receptor

ligands, hyaluronidase inhibitors, hepatitis b surface antigen (HBsAg) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ip4) inhibitors, cyclophilin inhibitors, HBV viral entry inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA) and ddRNAi endonuclease modulators, ribonucleotide reductase inhibitors, HBV E antigen inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor agonists, HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1, bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors, and other HBV drugs.

66. The use according to any one of claims 63 to 65, wherein the one or more additional therapeutic agents are selected from adefovir (HEPSERA®), tenofovir disoproxil fumarate (VIREAD®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE®), telbivudine (TYZEKA®), and lamivudine (EPIVIR-HBV®).

67. The use according to any one of claims 63 to 66, wherein the one or more additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.